clinical trial · NCT01848561
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie·—·active not recruiting·n = 8,250
Ulcerative Colitis (UC)
brief summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
started
Apr 29, 2013
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Jul 16, 2025
official title
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol